WASHINGTON, D.C. — The Myc oncogene can disrupt the 24-hour internal rhythm in cancer cells. Postdoctoral fellow Brian Altman, PhD, and graduate student Annie Hsieh, MD, both from the in the lab of Chi Van Dang, MD, PhD, director of the Abramson Cancer Center, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, present their data in the “Metabolic Pathway Regulation in Cancer” session at the 2013 American Association for Cancer Research meeting, Washington, D.C., April 9, 2013.
Timing of the body's molecular clock in normal cells synchronizes the cellular need for energy with food intake during our sleep-wake cycle. Timing matters to the study of cancer in two ways. First, toxicity to some chemotherapy drugs is related to time of day. For example, a cancer drug called 5-flourouracil is less toxic if given to a patient at night because the liver enzymes that detoxify it are more abundant at night.
Second, several circadian rhythm genes have been implicated as tumor suppressors, although those exact connections are as yet unclear. Other researchers have also observed that many, but not all, cancer cell cultures lack proper circadian rhythm.
"Our hypothesis is that disrupting circadian rhythm benefits cancer cells by unleashing their metabolism from the constraints of the molecular clock," says Altman. "In this regard, cancers don't sleep; they don't rest."
The Penn study deals with the relationship of clock proteins in peripheral tissues associated with three types of cancer cells. The researchers surmise that Myc may affect circadian rhythm by promiscuously binding to promoter regions in key genes for maintaining circadian rhythm. In fact, using a well known genome browser they confirmed that Myc binds to circadian genes. The Penn team also found that Myc upregulates another clock-regulated protein called NAMPT, potentially leading to dysregulated Sirt1 activity, another protein that is part of the complicated molecular clock.
Inhibiting NAMPT downstream of Myc also led to changes in circadian gene expression, suggesting a role for the modulation of other proteins downstream of Myc in throwing a wrench in the clock's gears.
Using cells from cultures of neuroblastoma, osteosarcoma, and hepatocellular carcinoma, which all overexpress Myc, they found that the abundance of Myc specifically upregulated the circadian protein Rev-erba. This protein in turn suppressed the oscillation of Bmal1 messenger RNA and decreased expression of the main clock protein Bmal1.
What's more, the disrupted circadian oscillations in the Myc-expressing cancer cells could be partially rescued by inhibiting expression of Rev-erba.
"Our data suggest that Myc-driven cancers have altered circadian oscillation due to upregulation of Rev-erba and NAMPT, and that these Myc cancers may be good candidates for chronotherapy," says Altman. "This work ties together the study of cell metabolism and cancer chronotherapy – If cells don't have to 'rest," they may replicate all the time, with no breaks at all."
"The understanding of these basic mechanisms from our work should lead to better cancer treatment strategies that reduce side effects and increase effectiveness" says Hsieh.
This study was funded by the National Cancer Institute (R01CA051497, R01CA57341) and the Leukemia and Lymphoma Society (636311).
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2013 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2013, Penn Medicine provided $814 million to benefit our community.
Department of Communications
For Patients and the General Public: